Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $23.15 and traded as low as $22.33. Collegium Pharmaceutical shares last traded at $22.60, with a volume of 237,003 shares changing hands.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Collegium Pharmaceutical in a research report on Friday, August 4th. Needham & Company LLC lifted their price target on shares of Collegium Pharmaceutical from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, August 25th. Finally, StockNews.com began coverage on shares of Collegium Pharmaceutical in a research report on Thursday, August 17th. They set a “buy” rating on the stock.
Read Our Latest Research Report on COLL
Collegium Pharmaceutical Trading Up 1.1 %
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.02. The business had revenue of $135.55 million during the quarter, compared to analyst estimates of $137.98 million. Collegium Pharmaceutical had a negative net margin of 2.08% and a positive return on equity of 87.81%. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 4.73 earnings per share for the current fiscal year.
Institutional Trading of Collegium Pharmaceutical
Several institutional investors have recently added to or reduced their stakes in COLL. Strs Ohio bought a new stake in Collegium Pharmaceutical during the second quarter valued at $25,000. Altshuler Shaham Ltd bought a new position in shares of Collegium Pharmaceutical during the fourth quarter worth about $28,000. West Tower Group LLC bought a new position in shares of Collegium Pharmaceutical during the second quarter worth about $43,000. Captrust Financial Advisors grew its position in shares of Collegium Pharmaceutical by 97.5% during the first quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock worth $44,000 after acquiring an additional 1,062 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Collegium Pharmaceutical by 233.9% during the first quarter. PNC Financial Services Group Inc. now owns 2,224 shares of the specialty pharmaceutical company’s stock worth $44,000 after acquiring an additional 1,558 shares during the last quarter.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Recommended Stories
- Five stocks we like better than Collegium Pharmaceutical
- Pros And Cons Of Monthly Dividend Stocks
- Nursing Home REITs: The Surprise Heroes of High Yield Investing
- 5 Top Rated Dividend Stocks to Consider
- Energy Stocks Shine as High Oil Prices Boost Dividend Yields
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
